• Aastrom Biosciences Inc., of Ann Arbor, Mich., closed its previously announced $22.5 million public offering of stock and warrants. The company sold 10 million units for $2.25 apiece, with each unit consisting of one common share and one warrant to purchase an additional share with an exercise price of $3.22. Net proceeds of $20.5 million will support Phase III trials of cell therapy for critical limb ischemia. Stifel Nicolaus Weisel acted as the sole book-running manager and Needham and Co. LLC and Roth Capital Partners served as co-managers for the financing.

• Genta Inc., of Berkeley Heights, N.J., received $5 million from a control account related to its $25 million private placement of convertible notes issued in March 2010. Proceeds will be used to determine survival data from Genta's Phase III trial of Genasense (oblimersen sodium) for melanoma and to accelerate development of other pipeline products.

• Nutra Pharma Corp., of Coral Springs, Fla., filed a registration statement noting that shareholder Lincoln Park Capital Fund LLC may sell up to 62 million shares, which at the current market price of 9 cents each would generate about $5.6 million. Nutra would not receive any of these proceeds but might receive $10 million under a separate purchase agreement with Lincoln. Nutra sells pain relievers and its ReceptoPharm subsidiary is developing neurological and autoimmune drugs, including RPI-78M for adrenomyeloneuropathy.